This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shariat, S. F. Articles by Slawin, K. M. Search for Related Content PubMed PubMed Citation Articles by Shariat, S. F. Articles by Slawin, K. M. Social Bookmarking                            What's this?

Preoperative Plasma Levels of Transforming Growth Factor Beta₁ (TGF-ß₁) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy

From the Matsunaga-Conte Prostate Cancer Research Center, Scott Department of Urology, and Department of Pathology, Baylor College of Medicine, and The Methodist Hospital, Houston, TX; and Departments of Urology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Kevin Mark Slawin, MD, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin St, Suite 2100, Houston, TX 77030; email: kslawin{at}www.urol.bcm.tmc.edu

PURPOSE: Elevated local and circulating levels of transforming growth factor beta₁ (TGF-ß₁) have been associated with prostate cancer invasion and metastasis. We tested the hypothesis that preoperative plasma TGF-ß₁ levels would independently predict cancer stage and prognosis in patients who undergo radical prostatectomy.

PATIENTS AND METHODS: The study group consisted of 120 consecutive patients who underwent radical prostatectomy for clinically localized prostate cancer (median follow-up, 53.8 months). Preoperative plasma levels of TGF-ß₁ were measured and correlated with pathologic parameters and clinical outcomes. TGF-ß₁ levels also were measured in 44 healthy men without cancer, in 19 men with prostate cancer metastatic to regional lymph nodes, and in 10 men with prostate cancer metastatic to bone.

RESULTS: Plasma TGF-ß₁ levels in patients with lymph node metastases (14.2 ± 2.6 ng/mL) and bone metastases (15.5 ± 2.4 ng/mL) were higher than those in radical prostatectomy patients (5.2 ± 1.3 ng/mL) and healthy subjects (4.5 ± 1.2 ng/mL) (P < .001). In a preoperative analysis, preoperative plasma TGF-ß₁ level and biopsy Gleason sum both were predictors of organ-confined disease (P = .006 and P = .006, respectively) and PSA progression (P < .001 and P = .021, respectively). In a postoperative multivariate analysis, preoperative plasma TGF-ß₁ level, pathologic Gleason sum, and surgical margin status were predictors of PSA progression (P = .020,P = .020, and P = .022, respectively). In patients who progressed, preoperative plasma TGF-ß₁ levels were higher in those with presumed distant compared with local-only failure (P = .019).

CONCLUSION: Plasma TGF-ß₁ levels are markedly elevated in men with prostate cancer metastatic to regional lymph nodes and bone. In men without clinical or pathologic evidence of metastases, the preoperative plasma TGF-ß₁ level is a strong predictor of biochemical progression after surgery, presumably because of an association with occult metastatic disease present at the time of radical prostatectomy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. F. Shariat, J. A. Karam, J. Walz, C. G. Roehrborn, F. Montorsi, V. Margulis, F. Saad, K. M. Slawin, and P. I. Karakiewicz Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers Clin. Cancer Res., June 15, 2008; 14(12): 3785 - 3791. [Abstract] [Full Text] [PDF]

				S. F. Shariat, J. Walz, C. G. Roehrborn, A. R. Zlotta, P. Perrotte, N. Suardi, F. Saad, and P. I. Karakiewicz External Validation of a Biomarker-Based Preoperative Nomogram Predicts Biochemical Recurrence After Radical Prostatectomy J. Clin. Oncol., March 20, 2008; 26(9): 1526 - 1531. [Abstract] [Full Text] [PDF]

				J. A. Karam, R. S. Svatek, P. I. Karakiewicz, A. Gallina, C. G. Roehrborn, K. M. Slawin, and S. F. Shariat Use of Preoperative Plasma Endoglin for Prediction of Lymph Node Metastasis in Patients with Clinically Localized Prostate Cancer Clin. Cancer Res., March 1, 2008; 14(5): 1418 - 1422. [Abstract] [Full Text] [PDF]

				S. Biswas, T. L. Criswell, S. E. Wang, and C. L. Arteaga Inhibition of Transforming Growth Factor-{beta} Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy. Clin. Cancer Res., July 15, 2006; 12(14): 4142 - 4146. [Full Text] [PDF]

				H.-W. Chen, Y.-C. Chang, Y.-L. Lai, Y.-J. Chen, M.-J. Huang, Y.-S. Leu, Y.-K. Fu, L.-W. Wang, and J.-J. Hwang Change of Plasma Transforming Growth Factor-{beta}1 Levels in Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemo-radiotherapy Jpn. J. Clin. Oncol., August 1, 2005; 35(8): 427 - 432. [Abstract] [Full Text] [PDF]

				R. L. Elliott and G. C. Blobe Role of Transforming Growth Factor Beta in Human Cancer J. Clin. Oncol., March 20, 2005; 23(9): 2078 - 2093. [Abstract] [Full Text] [PDF]

				L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]

				R. S. Muraoka-Cook, H. Kurokawa, Y. Koh, J. T. Forbes, L. R. Roebuck, M. H. Barcellos-Hoff, S. E. Moody, L. A. Chodosh, and C. L. Arteaga Conditional Overexpression of Active Transforming Growth Factor {beta}1 In vivo Accelerates Metastases of Transgenic Mammary Tumors Cancer Res., December 15, 2004; 64(24): 9002 - 9011. [Abstract] [Full Text] [PDF]

				A. Ewart-Toland, J. M. Chan, J. Yuan, A. Balmain, and J. Ma A Gain of Function TGFB1 Polymorphism May Be Associated With Late Stage Prostate Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 759 - 764. [Abstract] [Full Text] [PDF]

				S. F. Shariat, M. W. Kattan, E. Traxel, B. Andrews, K. Zhu, T. M. Wheeler, and K. M. Slawin Association of Pre- and Postoperative Plasma Levels of Transforming Growth Factor {beta}1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression Clin. Cancer Res., March 15, 2004; 10(6): 1992 - 1999. [Abstract] [Full Text] [PDF]

				Z. Li, T. Habuchi, N. Tsuchiya, K. Mitsumori, L. Wang, C. Ohyama, K. Sato, T. Kamoto, O. Ogawa, and T. Kato Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10 Carcinogenesis, February 1, 2004; 25(2): 237 - 240. [Abstract] [Full Text] [PDF]

				A. Aigner, P. Brachmann, J. Beyer, R. Jager, D. Raulais, M. Vigny, A. Neubauer, A. Heidenreich, S. Weinknecht, F. Czubayko, et al. Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients Ann. Onc., October 1, 2003; 14(10): 1525 - 1529. [Abstract] [Full Text] [PDF]

				M.-E. Taplin and P. W. Kantoff The Ingredients for Prostate Cancer Nomograms: The Addition of Biomarkers Sets the Table for Future Recipes J. Clin. Oncol., October 1, 2003; 21(19): 3552 - 3553. [Full Text] [PDF]

				M. W. Kattan, S. F. Shariat, B. Andrews, K. Zhu, E. Canto, K. Matsumoto, M. Muramoto, P. T. Scardino, M. Ohori, T. M. Wheeler, et al. The Addition of Interleukin-6 Soluble Receptor and Transforming Growth Factor Beta1 Improves a Preoperative Nomogram for Predicting Biochemical Progression in Patients With Clinically Localized Prostate Cancer J. Clin. Oncol., October 1, 2003; 21(19): 3573 - 3579. [Abstract] [Full Text] [PDF]

				S. F. Shariat, M. W. Kattan, W. Song, D. Bernard, E. Gottenger, T. M. Wheeler, and K. M. Slawin Early Postoperative Peripheral Blood Reverse Transcription PCR Assay for Prostate-specific Antigen Is Associated with Prostate Cancer Progression in Patients Undergoing Radical Prostatectomy Cancer Res., September 15, 2003; 63(18): 5874 - 5878. [Abstract] [Full Text] [PDF]

				S. F. Shariat, M. P. Roudier, G. E. Wilcox, M. W. Kattan, P. T. Scardino, R. L. Vessella, S. Erdamar, C. Nguyen, T. M. Wheeler, and K. M. Slawin Comparison of Immunohistochemistry with Reverse Transcription-PCR for the Detection of Micrometastatic Prostate Cancer in Lymph Nodes Cancer Res., August 1, 2003; 63(15): 4662 - 4670. [Abstract] [Full Text] [PDF]

				K. L. Weber and M. C. Gebhardt What's New in Musculoskeletal Oncology J. Bone Joint Surg. Am., March 31, 2003; 85(4): 761 - 767. [Full Text] [PDF]

				S. F. Shariat, E. Gottenger, C. Nguyen, W. Song, M. W. Kattan, J. Andenoro, T. M. Wheeler, D. M. Spencer, and K. M. Slawin Preoperative Blood Reverse Transcriptase-PCR Assays for Prostate-specific Antigen and Human Glandular Kallikrein for Prediction of Prostate Cancer Progression after Radical Prostatectomy Cancer Res., October 15, 2002; 62(20): 5974 - 5979. [Abstract] [Full Text] [PDF]

				G. Giannelli, E. Fransvea, F. Marinosci, C. Bergamini, S. Colucci, O. Schiraldi, and S. Antonaci Transforming Growth Factor-{beta}1 Triggers Hepatocellular Carcinoma Invasiveness via {alpha}3{beta}1 Integrin Am. J. Pathol., July 1, 2002; 161(1): 183 - 193. [Abstract] [Full Text] [PDF]